StockpollyBeta
Get App
Popularity #1,867
LENZ · NASDAQ · Biotechnology

LENZ (LENZ)

Commercializes VIZZ, an FDA-approved aceclidine eye drop for adult presbyopia.

$4.18
After hours+0.05 (+1.26%)
At close$4.13(+1.10%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000513225
Cost of revenue000000000110
Gross profit0000000512115
202516141315172231404539
Research & development172011766694000
356769111327404539
General & administrative0000000000039
Operating income−20−25−16−14−13−15−17−17−19−38−44−34
11−1433222332
Interest income101233222332
Other non-operating income0−11−4−3−3−2−2−2−3−3−2
Income before tax−19−24−17−10−10−13−15−14−17−36−41−32
Income tax expense000000010000
Net income from continuing operations−19−24−17−10−10−13−15−15−17−36−41−32
Net income−19−24−17−10−10−13−15−15−17−36−41−32
EPS, basic−$2.75−$2.77−$3.53−$0.40−$0.38−$0.46−$0.53−$0.53−$0.59−$1.16−$1.32−$1.02
EPS, diluted−$2.75−$2.77−$3.53−$0.40−$0.38−$0.46−$0.53−$0.53−$0.59−$1.16−$1.32−$1.02
Weighted average shares, basic885262727282829313131
Weighted average shares, diluted885262727282829313131
EBITDA−20−24−17−10−10−13−15−14−17−36−41−32
Depreciation & amortization000000000000
EBIT−20−24−17−10−10−13−15−14−17−36−41−32